Metformin Dosing in CKD Stage 3B
For patients with CKD stage 3B (eGFR 30-44 mL/min/1.73 m²), reduce the metformin dose to a maximum of 1000 mg daily, divided as 500 mg twice daily. 1
Dosing Algorithm by eGFR
The 2022 KDIGO guidelines provide clear, evidence-based dosing recommendations 1:
For eGFR 30-44 mL/min/1.73 m² (CKD Stage 3B):
- Maximum daily dose: 1000 mg (halve the usual dose)
- Typical regimen: 500 mg twice daily
- If initiating therapy: Start with 500 mg once daily, may titrate to 500 mg twice daily based on tolerance
- Do NOT initiate metformin if patient is not already on it - this is explicitly not recommended 1, 2
For eGFR 45-59 mL/min/1.73 m² (CKD Stage 3A):
- Maximum daily dose: 1500 mg
- Typical regimen: 500 mg in morning + 1000 mg in evening 3
- Consider dose reduction in patients with additional risk factors for lactic acidosis (heart failure, liver disease, respiratory insufficiency)
For eGFR ≥60 mL/min/1.73 m²:
- Continue usual dose (up to 2000-2550 mg daily)
- No adjustment needed
For eGFR <30 mL/min/1.73 m² (CKD Stage 4-5):
Critical Monitoring Requirements
Increase monitoring frequency when eGFR <60 mL/min/1.73 m² 1, 2:
- Check eGFR every 3-6 months (not annually)
- Monitor for signs of lactic acidosis (malaise, myalgias, respiratory distress, abdominal pain)
- Check vitamin B12 levels if on metformin >4 years 1
Important Clinical Caveats
When to Stop Metformin Temporarily:
Even with appropriate eGFR, discontinue metformin in these situations 4:
- Before iodinated contrast procedures (if eGFR 30-60 mL/min/1.73 m²)
- During acute illness causing volume depletion or hypoperfusion
- Acute heart failure with hypoxemia
- Sepsis or conditions causing tissue hypoxia
- Acute myocardial infarction
- Hepatic impairment
Rationale for Dose Reduction:
Metformin is eliminated unchanged by the kidneys 2, 3. In CKD stage 3B, reduced clearance leads to drug accumulation. Research demonstrates that 1000 mg daily maintains plasma metformin concentrations below the 5 mg/L safety threshold while preserving efficacy (target >1 mg/L) 3, 5. Higher doses risk accumulation and potential lactic acidosis, though the absolute risk remains low with appropriate dosing 3, 6.
Evidence Quality:
The KDIGO 2022 guideline 1 represents the highest quality, most recent evidence (Grade 1B recommendation). This is reinforced by FDA labeling 4 and supported by pharmacokinetic studies demonstrating safety of dose-adjusted metformin in moderate CKD 3. The Korean consensus 6 and Australian research 5 provide concordant recommendations.
Special Consideration for Very Elderly:
Recent 2026 data suggests increased caution in patients >78 years with CKD, showing higher rates of adverse outcomes including ICU admission and lactic acidosis 7. In this population, consider even more conservative dosing or alternative agents, particularly if multiple comorbidities exist.
If Patient Cannot Take Metformin:
When eGFR falls below 45 mL/min/1.73 m² and metformin must be reduced or stopped, SGLT2 inhibitors are recommended as first-line therapy for patients with eGFR ≥20 mL/min/1.73 m², as they provide kidney and cardiovascular protection independent of glycemic control 1, 2.